ABBV US00287Y1091

Report

Delayed Nyse - 09/17 04:10:00 pm
107.73	USD		-0.32%

09/16	ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults With Ulcerative Colitis	MT
09/16	ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	PR
09/16	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	CI

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

09/13/2021	09/14/2021	09/15/2021	09/16/2021	09/17/2021	Date
107.48(c)	106.48(c)	107.77(c)	108.08(c)	107.73(c)	Last
7 398 901	6 102 705	7 444 253	5 821 818	13 488 909	Volume
+0.75%	-0.93%	+1.21%	+0.29%	-0.32%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	56 247 M - -
Net income 2021	12 652 M - -
Net Debt 2021	66 393 M - -
P/E ratio 2021	14,6x
Yield 2021	4,76%

Sales 2022	59 589 M - -
Net income 2022	15 370 M - -
Net Debt 2022	53 426 M - -
P/E ratio 2022	11,9x
Yield 2022	5,13%

Capitalization	190 B 190 B -
EV / Sales 2021	4,57x
EV / Sales 2022	4,09x
Nbr of Employees	48 000
Free-Float	98,0%

More Financials

Company

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human...

Sector

Pharmaceuticals

Calendar

10/14

Ex-dividend day for

More about the company

Ratings of AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about ABBVIE INC.

09/16	ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Trea..	MT
09/16	ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ..	PR
09/16	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for th..	CI
09/16	AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis	DJ
09/15	China's biotech sector comes of age with big licensing deals, global ambition..	RE
09/14	ABBVIE : and REGENXBIO Announce Eye Care Collaboration	AQ
09/14	REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care D..	MT
09/13	Health Care Stocks Still Adding to Afternoon Slide	MT
09/13	Health Care Stocks Slipping Monday Afternoon	MT
09/13	REGENXBIO : Partners with AbbVie to Commercialize RGX-314 for Retinal Eye Diseas..	MT
09/13	ABBVIE : Declares Quarterly Dividend	AQ
09/13	ABBVIE : to Highlight Its Leadership in Movement Disorders at the International ..	AQ
09/13	APPLE : Energy, financials help Wall Street rise from bruising week	RE
09/13	Wall Street Set for Rebound After Week of Losses	MT
09/13	Regenxbio Shares Jump After Collaborating With AbbVie on Eye Therapy	DJ

More news

News in other languages on ABBVIE INC.

09/16	AbbVie dépose des demandes d'homologation aux États-Unis et en Europe pour l'..
09/13	Les actions du secteur de la santé continuent de s'enfoncer dans l'après-midi
09/13	Les actions du secteur de la santé en baisse lundi après-midi
09/13	REGENXBIO s'associe à AbbVie pour commercialiser le RGX-314 contre les maladi..
09/13	ABBVIE : partenariat avec Regenxbio

More news

Analyst Recommendations on ABBVIE INC.

09/14	REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care D..	MT
09/02	ABBVIE : SVB Leerink Adjusts AbbVie PT to $142 From $148, Maintains Outperform R..	MT
08/23	ABBVIE : Cowen Adjusts AbbVie's Price Target to $130 From $120, Reiterates Outpe..	MT

More recommendations

Provided by Scoopnest.com

Analysis

China's biotech sector comes of age with big licensing deals, global ambitions